应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
GSK 葛兰素史克
盘后交易 06-08 17:43:25 EDT
50.64
-0.88
-1.71%
盘后
50.64
+0.00
0.00%
16:15 EDT
最高
51.38
最低
50.46
成交量
483.64万
今开
50.99
昨收
51.52
日振幅
1.78%
总市值
1,026亿
流通市值
985.91亿
总股本
20.26亿
成交额
2.46亿
换手率
0.25%
流通股本
19.47亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
异动解读｜葛兰素史克盘中上涨3.01%，乙肝功能性治愈新药三期数据积极且中国上市加速推进
行情直击 · 06-05
异动解读｜葛兰素史克盘中上涨3.01%，乙肝功能性治愈新药三期数据积极且中国上市加速推进
港股异动 | 中国生物制药(01177)涨超4% 与GSK合作的Bepirovirsen将于EASL 2026公布两项III期临床数据
智通财经 · 05-29
港股异动 | 中国生物制药(01177)涨超4% 与GSK合作的Bepirovirsen将于EASL 2026公布两项III期临床数据
全球首项乙肝功能性治愈药物三期数据来了：这类患者，治愈率可达35%
第一财经 · 05-28
全球首项乙肝功能性治愈药物三期数据来了：这类患者，治愈率可达35%
重磅ADC药物获批多发性骨髓瘤二线联合用药，GSK中国特药业务部负责人：肿瘤是未来GSK重要增长引擎之一
蓝鲸财经 · 05-19
重磅ADC药物获批多发性骨髓瘤二线联合用药，GSK中国特药业务部负责人：肿瘤是未来GSK重要增长引擎之一
流行病诊疗板块多股扬升 雅培(ABT)涨1.60%、强生(JNJ)涨1.12%
金吾财讯 · 05-12
流行病诊疗板块多股扬升 雅培(ABT)涨1.60%、强生(JNJ)涨1.12%
中国生物制药涨超4%：牵手GSK合作乙肝临床治愈明星产品
澎湃新闻 · 05-11
中国生物制药涨超4%：牵手GSK合作乙肝临床治愈明星产品
正大天晴牵手GSK，瞄准乙肝百亿美元赛道商业化棋局
21世纪经济报道 · 05-11
正大天晴牵手GSK，瞄准乙肝百亿美元赛道商业化棋局
港股异动 | 中国生物制药(01177)午后涨超4% 正大天晴与葛兰素史克合作乙肝治愈重磅新药
智通财经 · 05-11
港股异动 | 中国生物制药(01177)午后涨超4% 正大天晴与葛兰素史克合作乙肝治愈重磅新药
中国生物制药(01177)与葛兰素史克达成独家战略合作
智通财经 · 05-11
中国生物制药(01177)与葛兰素史克达成独家战略合作
时安生物与GSK就寡核苷酸新药达成超10亿美元授权合作；莎普爱思终止购买上海勤礼实业100%股权｜医药早参
每日经济新闻 · 05-07
时安生物与GSK就寡核苷酸新药达成超10亿美元授权合作；莎普爱思终止购买上海勤礼实业100%股权｜医药早参
花旗：将葛兰素史克目标价下调至2100便士
中金财经 · 05-06
花旗：将葛兰素史克目标价下调至2100便士
新掌门首份成绩单亮眼：HIV与抗癌药立功 葛兰素史克(GSK.US)Q1营收利润双超预期
智通财经 · 04-29
新掌门首份成绩单亮眼：HIV与抗癌药立功 葛兰素史克(GSK.US)Q1营收利润双超预期
葛兰素史克Q1业绩超市场预期，预计全年盈利增长7%至9%
老虎资讯综合 · 04-29
葛兰素史克Q1业绩超市场预期，预计全年盈利增长7%至9%
从“抗艾第一股”到小核酸新贵 前沿生物股价与业绩齐飞 靠GSK千万美元授权金逆势涨停
时代财经 · 04-27
从“抗艾第一股”到小核酸新贵 前沿生物股价与业绩齐飞 靠GSK千万美元授权金逆势涨停
葛兰素史克(GSK.US)Belantamab mafodotin(玛贝兰妥单抗)在华获批上市
智通财经 · 04-17
葛兰素史克(GSK.US)Belantamab mafodotin(玛贝兰妥单抗)在华获批上市
超长效呼吸生物制剂德莫奇单抗获批新适应症
南方财经网 · 04-08
超长效呼吸生物制剂德莫奇单抗获批新适应症
葛兰素史克(GSK.US)超长效单抗新药新适应症在中国获批上市
智通财经 · 04-03
葛兰素史克(GSK.US)超长效单抗新药新适应症在中国获批上市
三星生物制剂2.8亿美元收购葛兰素史克美国工厂
环球市场播报 · 04-01
三星生物制剂2.8亿美元收购葛兰素史克美国工厂
葛兰素史克德莫奇单抗获批上市，系中国首款治疗嗜酸性表型重度哮喘的超长效生物制剂
北京商报 · 03-31
葛兰素史克德莫奇单抗获批上市，系中国首款治疗嗜酸性表型重度哮喘的超长效生物制剂
曾长期缺货，葛兰素史克乙肝疫苗安在时重返中国市场
红星资本局 · 03-26
曾长期缺货，葛兰素史克乙肝疫苗安在时重返中国市场
加载更多
公司概况
公司名称：
葛兰素史克
所属市场：
NYSE
上市日期：
--
主营业务：
GSK Plc于1999年12月6日在英国成立的公众服务有限公司，是一个世界领先的研究型制药和保健公司，由Glaxo Wellcome plc和SmithKline Beecham plc合并而成。公司致力于开发较现有治疗方案明显改善的新产品，为病人和政府、保险公司或其他第三方提供帮助。
发行价格：
--
{"stockData":{"symbol":"GSK","market":"US","secType":"STK","nameCN":"葛兰素史克","latestPrice":50.64,"timestamp":1780948800000,"preClose":51.52,"halted":0,"volume":4836404,"hourTrading":{"tag":"盘后","latestPrice":50.64,"preClose":50.64,"latestTime":"16:15 EDT","volume":21787,"amount":1103293.68,"timestamp":1780949712218,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.017080745341614956,"floatShares":1946891708,"shares":2025750558,"eps":3.736205,"marketStatus":"盘后交易","change":-0.88,"latestTime":"06-08 17:43:25 EDT","open":50.99,"high":51.375,"low":50.46,"amount":245808104,"amplitude":0.01776,"askPrice":50.75,"askSize":173,"bidPrice":50.51,"bidSize":173,"shortable":3,"etf":0,"ttmEps":3.736205,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1780963200000},"marketStatusCode":4,"adr":1,"adrRate":2,"listingDate":977893200000,"exchange":"NYSE","adjPreClose":51.52,"dividendRate":0.035663,"preHourTrading":{"tag":"盘前","latestPrice":51.02,"preClose":51.52,"latestTime":"09:27 EDT","volume":7774,"amount":397678.845616,"timestamp":1780925220079,"change":-0.5,"changeRate":-0.009705,"amplitude":0.010307},"postHourTrading":{"tag":"盘后","latestPrice":50.64,"preClose":50.64,"latestTime":"16:15 EDT","volume":21787,"amount":1103293.68,"timestamp":1780949712218,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.28975,"impliedVol":0.2768,"impliedVolPercentile":0.3506},"requestUrl":"/m/hq/s/GSK","defaultTab":"news","newsList":[{"id":"1184442827","title":"异动解读｜葛兰素史克盘中上涨3.01%，乙肝功能性治愈新药三期数据积极且中国上市加速推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1184442827","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184442827?lang=zh_cn&edition=full","pubTime":"2026-06-05 03:53","pubTimestamp":1780602815,"startTime":"0","endTime":"0","summary":"6月5日，葛兰素史克盘中上涨3.01%，报51.22美元/股，成交额1.69亿美元。研究显示，该药6个月治疗后总体功能性治愈率达19%，低基线病毒活性人群治愈率达26%，中国亚组中HBsAg≤1000 IU/mL患者治愈率高达35%，安慰剂组为0%。此外，该药已在中国再次提交上市申请并获受理，纳入优先审评，GSK预计2027年上半年获中国药监局审批决定。杰富瑞预测其峰值年销售额达15亿美元，GSK内部预期更为乐观，有望突破27亿美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639644648","title":"港股异动 | 中国生物制药(01177)涨超4% 与GSK合作的Bepirovirsen将于EASL 2026公布两项III期临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2639644648","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639644648?lang=zh_cn&edition=full","pubTime":"2026-05-29 14:33","pubTimestamp":1780036423,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国生物制药涨超4%，截至发稿，涨3.95%，报5港元，成交额4.28亿港元。消息面上，5月29日，中国生物制药发布公告，本集团附属公司正大天晴药业集团股份有限公司与葛兰素史克合作的Bepirovirsen，已公布其用于治疗慢性乙型肝炎的积极关键数据。Bepirovirsen目前正在接受中国、美国、欧洲、日本监管机构的审评审批。GSK预计2027年上半年收到中国国家药品监督管理局的监管决定，目前上市准备工作正在进行中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447644.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","BK1589","BK4588","VXUS","LU1829250122.USD","GSKH","01177","BK4007","BK1521","BK1191","GSK","BK4532","GSK.UK","IE00BZ08YT58.USD","III","BK4585","BK4134","IE00BZ08YR35.GBP","BK1515","IE00BZ08YS42.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638698093","title":"全球首项乙肝功能性治愈药物三期数据来了：这类患者，治愈率可达35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638698093","media":"第一财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638698093?lang=zh_cn&edition=full","pubTime":"2026-05-28 20:00","pubTimestamp":1779969642,"startTime":"0","endTime":"0","summary":"被视为有可能成为全球首款乙肝功能性治愈药物的贝普若韦生（Bepirovirsen），三期临床研究结果揭晓了。5月28日，葛兰素史克（GSK）在欧洲肝病学会（EASL）年会上公布了反义寡核苷酸（ASO）药物贝普若韦生两项全球三期临床试验（B-Well1和B-Well2）结果。结果也发表在全球顶刊《新英格兰医学杂志》上。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605283752957045.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605283752957045.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1829250122.USD","GSK.UK","BK4588","GSK","GSKH","NA","BK4200","ASO","BK4585","BK4007","BK4561","BK4141","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636356678","title":"重磅ADC药物获批多发性骨髓瘤二线联合用药，GSK中国特药业务部负责人：肿瘤是未来GSK重要增长引擎之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2636356678","media":"蓝鲸财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636356678?lang=zh_cn&edition=full","pubTime":"2026-05-19 15:41","pubTimestamp":1779176518,"startTime":"0","endTime":"0","summary":"值得注意的是，倍乐锐是GSK肿瘤领域的重磅药物。据GSK全球一季度财报，该药物在今年一季度收入达2300万英镑，在该款药物的加持下，肿瘤业务也已经是GSK当前业绩增长最快的板块。今年第一季度，GSK肿瘤业务销售额同比增长28%，达到5.12亿英镑，业务增速在所有业务中位居第一。GSK副总裁、中国特药业务部负责人张宁向蓝鲸新闻表示，GSK未来会考虑布局更多的ADC药物、小分子药物等形成合力，包括肿瘤在内的特药业务是未来GSK很重要的增长引擎之一。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1779176429659930072","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["ADC","BK4231","BK4588","LU1829250122.USD","BK4532","GSK","BK4080","BK4585","GSKH","GSK.UK","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634101862","title":"流行病诊疗板块多股扬升 雅培(ABT)涨1.60%、强生(JNJ)涨1.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2634101862","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634101862?lang=zh_cn&edition=full","pubTime":"2026-05-12 22:05","pubTimestamp":1778594751,"startTime":"0","endTime":"0","summary":"金吾财讯 | 汉坦病毒疫情叠加药企药物研发/合作进展向好消息提振，美股流行病诊疗板块多股扬升，截至发稿，葛兰素史克 涨 1.93%，雅培 涨 1.60%，默沙东 涨 1.41%，阿斯利康 涨 1.18%，强生 涨 1.12%。达歌生物周二宣布与默沙东研发(中国)有限公司签署合作协议，共同推进抗肿瘤药物临床合作开发。","market":"other","thumbnail":"https://static.szfiu.com/news/20250107/MzZmY2I0ODMyNDljNDZhYjk1YmMwYzA2ZTYzZmI3NWMyMTczNjIzMDYxMjY4Mg==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/MzZmY2I0ODMyNDljNDZhYjk1YmMwYzA2ZTYzZmI3NWMyMTczNjIzMDYxMjY4Mg==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"300341","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0861579265.USD","LU1551013425.SGD","LU0070217475.USD","LU1989772840.SGD","LU2324357040.USD","LU1043141123.HKD","LU2129689431.USD","LU1267930813.SGD","LU1430594728.SGD","IE00BBT3K403.USD","IE0001KFT4U8.USD","LU1718418525.SGD","LU1917777945.USD","IE00B3T34201.USD","LU1571399168.USD","LU2023250843.SGD","LU0648001328.SGD","LU1506573853.SGD","LU1551013342.USD","IE00BJT1NW94.SGD","LU1280957306.USD","LU2430703095.HKD","SG9999001176.USD","LU2237443465.HKD","LU2491050071.SGD","LU0320765992.SGD","BK4504","LU2133065610.SGD","IE00B3PB1722.GBP","IE00B7SZLL34.SGD","LU1057294990.SGD","LU2505996681.GBP","LU2237957902.USD","LU0868494708.USD","LU1201861249.SGD","LU0477156953.USD","BK4585","IE00B1BXHZ80.USD","LU1059921491.USD","LU0820562030.AUD","LU2471134879.HKD","LU1989763690.USD","LU1291159041.SGD","LU0289739699.SGD","LU2756315318.SGD","LU0208291251.USD","LU1093756325.SGD","LU1941712264.USD","LU2347655156.SGD","IE00B2B36J28.USD","LU0965509010.AUD","IE000SO60NU8.SGD","LU0942090050.USD","LU1023059063.AUD","LU1894683348.USD","IE00BLSP4452.SGD","LU0266013472.USD","LU1629891620.HKD","LU2487616109.SGD","LU0211331839.USD","LU0889565916.HKD","SG9999004303.SGD","IE0002141913.USD","LU1032466523.USD","LU1061106388.HKD","LU0889566641.SGD","LU2750360997.AUD","LU1778281490.HKD","LU1032955483.USD","LU2403377893.USD","IE0009355771.USD","LU0130102774.USD","LU0426417589.USD","LU1093756168.USD","LU1121112475.USD","LU2125154935.USD","LU2361045086.USD","LU2430703178.SGD","MRK","ABT","SG9999002224.SGD","LU0912757837.SGD","LU0683600562.USD","BK4534","GSK","LU0170899867.USD","LU2023250504.SGD","LU0426412945.USD","LU2750360641.GBP","LU0943347566.SGD","LU2756315664.SGD","LU2896262040.SGD","LU2125154778.USD","LU1929549753.HKD","LU2213496289.HKD","SG9999014575.USD","LU2505996509.AUD","IE00BFTCPJ56.SGD","LU0965508806.USD","BK4566","BK4550","LU0109394709.USD","LU0098860793.USD","LU0868494617.USD","LU1974910355.USD","LU0859254822.USD","SG9999014542.SGD","SG9999014567.USD","LU1914381329.SGD","LU0265550946.USD","LU1934455863.HKD","LU0070302665.USD","SGXZ41872573.SGD","IE00BGHQF631.EUR","IE000BZT7R73.USD","LU1496350502.SGD","BK4592","IE00B19Z3B42.SGD","LU1145028129.USD","LU0787776722.HKD","LU1066051498.USD","LU1989763427.SGD","LU1989772923.USD","LU2237443622.USD","IE00BKVL7J92.USD","LU0238689110.USD","AZN","LU0106261372.USD","LU1035773651.USD","LU1066053197.SGD","LU2237443978.SGD","LU1244550221.USD","LU0203345920.USD","LU2461242641.AUD","SG9999014559.SGD","LU1196500208.SGD","LU0234570918.USD","SGXZ23171101.USD","LU2237957811.SGD","LU2592432038.USD","LU1732799900.SGD","LU1037948897.HKD","LU1221951046.USD","LU0689472784.USD","LU0006306889.USD","LU0210536198.USD","LU2237443895.HKD","IE00BVYPNW00.USD","LU2361044865.SGD","SG9999002232.USD","LU1691799644.USD","LU2106854487.HKD","IE00BFXG1179.USD","LU0320765646.SGD","LU1261432733.SGD","LU0820561909.HKD","LU2491049909.HKD","LU1069347547.HKD","LU0210528500.USD","BK4568","LU2491050154.USD","BK4533","LU0795875086.SGD","BK4532","IE00BJJMRZ35.SGD","LU0124676726.USD","LU2129689514.USD","LU0345769128.USD","LU2417539215.USD","LU0545562505.USD","BK4559","LU1221951129.SGD","LU2471134796.USD","IE00B19Z3581.USD","LU0345769631.USD","LU1228905540.USD","LU2456880835.USD","BK4581","LU1721429402.USD","LU1674673428.USD","IE00B42XCP33.USD","LU0985320562.USD","LU0640476718.USD","LU1043141396.HKD","IE000WAW04H5.SGD","SG9999001440.SGD","LU1116320737.USD","LU2237443549.SGD","LU1829250122.USD","LU0689626769.HKD","LU2471134952.CNY","LU2468319806.SGD","LU0345770993.USD","LU0882574055.USD","IE00BLSP4239.USD","LU0058720904.USD","LU0965509101.SGD","IE000M9KFDE8.USD","SG9999015341.SGD","LU0964807845.USD","LU1066051225.USD","IE00BZ1G4Q59.USD","LU1934455194.USD","SG9999015358.SGD","SGXZ57979304.SGD","LU1989771016.USD","LU1244550577.SGD","LU0980610538.SGD","LU2237443382.USD","IE00B4R5TH58.HKD","LU0265550359.USD","LU0053666078.USD","IE00BSNM7G36.USD","BK4588","LU0466842654.USD","IE0002270589.USD","LU0792757196.USD","LU0203347892.USD","LU1732800096.USD","AZNH","LU1228905037.USD","LU2361044949.HKD","IE0034235303.USD","BK4082","GSK.UK","IE000F7OJYX1.SGD","LU1244550494.USD","BK4516","LU0345770308.USD","LU1162221912.USD","LU1074936037.SGD","IE00BVYPNV92.GBP","LU0130517989.USD","LU0122379950.USD","GSKH","LU0114720955.EUR","LU0795875169.SGD","LU2129689605.HKD","LU1674673691.USD","LU2089984988.USD","BK4007","LU1699723380.USD","LU2462157665.USD","LU0432979614.USD","LU1116320901.HKD","LU2430703251.USD","LU0965509283.SGD","LU2112291526.USD","LU1935042991.SGD","LU1941712348.USD","LU2211815571.USD","LU2360032135.SGD","LU0320765489.SGD","LU2471134523.USD","LU2602419157.SGD","IE00BN8TJ469.HKD","LU2357627491.SGD","LU0994945656.USD","LU1066051811.HKD","LU1934455277.USD","LU1983299246.USD","LU2023250330.USD","LU1037948541.HKD","SG9999001176.SGD","LU1721429741.USD","IE000MB6IJN5.SGD","LU0234572021.USD","LU1585245621.USD","LU0820561818.USD","LU2236285917.USD","JNJ","LU1894683264.USD","SG9999013999.USD","IE00BDGV0183.EUR","IE0000B7K699.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2634338289","title":"中国生物制药涨超4%：牵手GSK合作乙肝临床治愈明星产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2634338289","media":"澎湃新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634338289?lang=zh_cn&edition=full","pubTime":"2026-05-11 19:58","pubTimestamp":1778500680,"startTime":"0","endTime":"0","summary":"全球首款有望最快实现乙肝功能性治愈的重磅药物被中国生物制药收入囊中！5月11日，中国生物制药（1177.HK）正式宣布，核心子公司正大天晴药业集团与知名跨国药企葛兰素史克（LSE/NYSE：GSK）达成独家战略合作，将加速一款名为bepirovirsen的药物在中国的上市进程。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605113733296932.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605113733296932.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01177","GSK.UK","BK4588","BK4585","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","GSK","BK1191","LU1829250122.USD","HK0000165453.HKD","GSKH","BK1589","IE00BZ08YT58.USD","BK4532","BK1515","BK4007","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634405436","title":"正大天晴牵手GSK，瞄准乙肝百亿美元赛道商业化棋局","url":"https://stock-news.laohu8.com/highlight/detail?id=2634405436","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634405436?lang=zh_cn&edition=full","pubTime":"2026-05-11 15:26","pubTimestamp":1778484360,"startTime":"0","endTime":"0","summary":"中国乙肝治疗药物市场正在迎来一个关键变量。5月11日，中国生物制药（1177.HK）公告，其核心子公司正大天晴与葛兰素史克（GSK）就反义寡核苷酸（ASO）药物Bepirovirsen达成独家战略合作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605113733015888.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605113733015888.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GSK.UK","BK4588","BK4585","BK4532","LU1829250122.USD","GSKH","GSK","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634010474","title":"港股异动 | 中国生物制药(01177)午后涨超4% 正大天晴与葛兰素史克合作乙肝治愈重磅新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2634010474","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634010474?lang=zh_cn&edition=full","pubTime":"2026-05-11 13:35","pubTimestamp":1778477746,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国生物制药午后涨超4%，截至发稿，涨4.05%，报5.65港元，成交额2.78亿港元。消息面上，中国生物制药午间公告，集团附属公司正大天晴与葛兰素史克达成一项独家战略合作，加速bepirovirsen在中国内地的上市进程。根据协议条款，正大天晴将在初始5.5年合作期内，按照约定的供应条款向GSK采购bepirovirsen。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440070.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","GSK","HK0000165453.HKD","BK1521","IE00BZ08YS42.EUR","BK4532","BK4588","VXUS","BK1515","GSK.UK","01177","GSKH","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","BK4585","BK1191","LU1829250122.USD","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634147972","title":"中国生物制药(01177)与葛兰素史克达成独家战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2634147972","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634147972?lang=zh_cn&edition=full","pubTime":"2026-05-11 12:26","pubTimestamp":1778473605,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，集团附属公司正大天晴药业集团股份有限公司与葛兰素史克达成一项独家战略合作，加速bepirovirsen在中国内地的上市进程。根据协议条款，正大天晴将在初始5.5年合作期内，按照约定的供应条款向GSK采购bepirovirsen。通过持续深化与全球领先药企的战略合作，集团进一步巩固了作为MNC在中国首选合作伙伴的行业领先地位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440068.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GSK","IE00BZ08YS42.EUR","BK1521","BK4585","01177","GSK.UK","BK1191","IE00BZ08YR35.GBP","HK0000165453.HKD","LU1829250122.USD","BK1589","IE00BZ08YT58.USD","BK1515","GSKH","BK4532","BK4588","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633512166","title":"时安生物与GSK就寡核苷酸新药达成超10亿美元授权合作；莎普爱思终止购买上海勤礼实业100%股权｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2633512166","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633512166?lang=zh_cn&edition=full","pubTime":"2026-05-07 07:00","pubTimestamp":1778108408,"startTime":"0","endTime":"0","summary":"丨2026年5月7日星期四丨NO.1时安生物与GSK就寡核苷酸新药达成超10亿美元授权合作时安生物宣布，与葛兰素史克（GSK）就SA030达成一项中国市场以外的全球独家许可协议。葛兰素史克将支付首付款，以及未来基于成功达成的开发、注册与商业化里程碑付款，总额最高达10.05亿美元；同时将按中国以外的全球产品净销售额支付分级特许权使用费。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605073729101163.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605073729101163.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK1161","BK4007","GSK","BK4532","159938","603168","09939","BK4588","BK1515","GSK.UK","GSKH","LU1829250122.USD","BK4585","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633905567","title":"花旗：将葛兰素史克目标价下调至2100便士","url":"https://stock-news.laohu8.com/highlight/detail?id=2633905567","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633905567?lang=zh_cn&edition=full","pubTime":"2026-05-06 13:37","pubTimestamp":1778045821,"startTime":"0","endTime":"0","summary":"花旗集团将葛兰素史克目标股价从2250便士下调至2100便士。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260506/32202409.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631056182","title":"新掌门首份成绩单亮眼：HIV与抗癌药立功 葛兰素史克(GSK.US)Q1营收利润双超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2631056182","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631056182?lang=zh_cn&edition=full","pubTime":"2026-04-29 14:54","pubTimestamp":1777445657,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，得益于HIV、癌症及免疫疾病领域的专科药物销售表现强劲，英国制药巨头葛兰素史克周三公布了超预期的第一季度财报，这为年初正式掌舵的新任首席执行官Luke Miels带来了有力支持。财报显示，截至3月31日，葛兰素史克实现营收76.3亿英镑，略高于市场预期的75.8亿英镑。自宣布Miels接任CEO以来，葛兰素史克股价已累计上涨约34%，显示出市场对其变革举措的初步认可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436066.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129840658","title":"葛兰素史克Q1业绩超市场预期，预计全年盈利增长7%至9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1129840658","media":"老虎资讯综合","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129840658?lang=zh_cn&edition=full","pubTime":"2026-04-29 14:09","pubTimestamp":1777442988,"startTime":"0","endTime":"0","summary":"4月29日，$葛兰素史克(GSK)$盘后一度涨超6%，随后快速回落！该公司第一季度营收76.3亿英镑，预估76.1亿英镑；第一季度调整后每股收益46.5便士，预估43.2便士。预计全年销售额（按固定汇率计算）增长3%至5%；预计全年调整后每股收益增长7%至9%；预计全年调整后营业利润增长7%至9%；预计2031年销售额将超过400亿英镑。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ca0e3dea87604e6a95a3bf5695c5bcab","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"葛兰素史克Q1业绩超市场预期，预计全年盈利增长7%至9%","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","GSK","IE00BQJZX424.USD","BK5011","LU0306807586.USD","LU1309081286.SGD","LU1015430645.USD","LU1400636657.SGD","LU0109981661.USD","LU1481600234.SGD","LU1645745479.HKD","LU2646069778.SGD","BK4585","LU0225771236.USD","LU0306806265.USD","LU1046248800.SGD","LU1400636574.HKD","IE00BWDBJ516.SGD","LU1098665638.USD","IE00B3T34201.USD","LU0203347892.USD","LU0985481810.HKD","LU1487256676.USD","LU1035777561.USD","LU0971552830.HKD","LU1064927863.SGD","SG9999013999.USD","SGXZ57979304.SGD","LU0321505439.SGD","LU0575583348.USD","BK4532","LU0203345920.USD","LU0225283273.USD","LU0971552673.USD","LU0545562505.USD","LU1228905037.USD","LU1481599808.USD","LU1829250122.USD","LU1670756490.USD","LU1202635105.USD","BK4007","GSKH","LU0161305163.EUR","IE0034235071.USD","LU1228905540.USD","LU0321505868.SGD","LU0289739699.SGD","LU0557290698.USD","LU0211331839.USD","LU1400636491.USD","SG9999001176.USD","LU1983299246.USD","LU0987226296.USD","LU1302929846.USD","LU0225284248.USD","LU0058720904.USD","SG9999001176.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630393046","title":"从“抗艾第一股”到小核酸新贵 前沿生物股价与业绩齐飞 靠GSK千万美元授权金逆势涨停","url":"https://stock-news.laohu8.com/highlight/detail?id=2630393046","media":"时代财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630393046?lang=zh_cn&edition=full","pubTime":"2026-04-27 18:46","pubTimestamp":1777286760,"startTime":"0","endTime":"0","summary":"4月27日，在医药股普遍承压、板块整体走弱的背景下，创新药企前沿生物（688221.SH）却逆势爆发，开盘后快速拉升触及20%的涨停板，截至收盘，前沿生物涨停封板，报22.74元/股。前沿生物成立于2003年，创始人谢东出生于1966年，曾领导和参与了多个艾滋病新药的全球开发与上市工作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604273720433081.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GSKH","688221","BK4532","BK4585","LU1829250122.USD","BK4588","BK4007","GSK","GSK.UK","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628064279","title":"葛兰素史克(GSK.US)Belantamab mafodotin(玛贝兰妥单抗)在华获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2628064279","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628064279?lang=zh_cn&edition=full","pubTime":"2026-04-17 16:39","pubTimestamp":1776415186,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月17日，国家药监局(NMPA)网站显示，葛兰素史克(GSK.US)的Belantamab mafodotin(玛贝兰妥单抗)在华获批上市。根据此前的优先审评信息，此次获批的适应症为联合硼替佐米和地塞米松治疗既往接受过至少一种治疗的多发性骨髓瘤成人患者。玛贝兰妥单抗是Seagen(已被辉瑞收购)开发的一款BCMA ADC。2009年12月，GSK与Seagen达成协议，获得该药物的研究、开发、生产和商业化权益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429939.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4532","LU1829250122.USD","GSK.UK","BK4585","IPOS","GSKH","BK4588","BK4007","GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625915966","title":"超长效呼吸生物制剂德莫奇单抗获批新适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2625915966","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625915966?lang=zh_cn&edition=full","pubTime":"2026-04-08 15:36","pubTimestamp":1775633787,"startTime":"0","endTime":"0","summary":"南方财经4月8日电，葛兰素史克（LSE/NYSE:GSK）今日宣布，中国国家药品监督管理局（NMPA）批准易适来?（德莫奇单抗）与鼻用糖皮质激素联合使用，治疗系统性糖皮质激素和/或手术治疗无法充分控制疾病的慢性鼻窦炎伴鼻息肉（CRSwNP）成人患者。这些患者在接受系统性糖皮质激素和/或手术后，病情仍未得到充分控制。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604083698007473.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GSK","LU1829250122.USD","BK4007","GSK.UK","BK4585","GSKH","BK4588","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624765321","title":"葛兰素史克(GSK.US)超长效单抗新药新适应症在中国获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2624765321","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624765321?lang=zh_cn&edition=full","pubTime":"2026-04-03 15:51","pubTimestamp":1775202696,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月3日，NMPA官网显示，葛兰素史克“德莫奇单抗”新适应症获批上市，用于治疗慢性鼻窦炎伴鼻息肉病。2025年12月，德莫奇单抗在美国迎来全球首批。2026年3月，德莫奇单抗首次登陆中国市场。本次是德莫奇单抗在国内获批的第 2 项适应症。GSK拥有实力雄厚、行业领先的呼吸产品管线。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425067.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"葛兰素史克(GSK.US)超长效单抗新药新适应症在中国获批上市","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GSK","GSKH","LU1829250122.USD","BK4585","GSK.UK","BK4588","BK4532","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624561681","title":"三星生物制剂2.8亿美元收购葛兰素史克美国工厂","url":"https://stock-news.laohu8.com/highlight/detail?id=2624561681","media":"环球市场播报","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624561681?lang=zh_cn&edition=full","pubTime":"2026-04-01 13:12","pubTimestamp":1775020320,"startTime":"0","endTime":"0","summary":"三星集团旗下生物技术公司三星生物制剂周三表示，已斥资 2.8 亿美元收购了英国制药巨头葛兰素史克在美国的一家工厂。 三星生物制剂公司在一份新闻稿中表示，位于马里兰州罗克维尔的这家工厂拥有6万升原料药的生产能力，使该公司的总产能达到84.5万升。 三星生物制剂表示，计划进一步投资以扩大工厂产能并升级技术，从而巩固其加强全球供应链和改善关键药物可及性的长期承诺。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-01/doc-inhsynau2671180.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["GSKH","BK4588","LU1829250122.USD","BK4585","BK4007","GSK","BK4532","GSK.UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623001503","title":"葛兰素史克德莫奇单抗获批上市，系中国首款治疗嗜酸性表型重度哮喘的超长效生物制剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2623001503","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623001503?lang=zh_cn&edition=full","pubTime":"2026-03-31 17:54","pubTimestamp":1774950879,"startTime":"0","endTime":"0","summary":"北京商报讯（记者丁宁）葛兰素史克近日宣布，中国国家药品监督管理局批准易适来（德莫奇单抗）用于成人和12岁及以上青少年重度嗜酸性粒细胞性哮喘的维持治疗。据了解，易适来获批用于重度哮喘的治疗是基于SWIFT-1和SWIFT-2两项Ⅲ期临床试验的研究数据。在这两项均联合标准治疗的研究中，相较于安慰剂组，德莫奇单抗每年给药两次，能持续减少哮喘急性发作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603313690543314.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603313690543314.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GSK.UK","GSKH","LU1829250122.USD","BK4532","BK4007","BK4588","GSK","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622850002","title":"曾长期缺货，葛兰素史克乙肝疫苗安在时重返中国市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2622850002","media":"红星资本局","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622850002?lang=zh_cn&edition=full","pubTime":"2026-03-26 20:36","pubTimestamp":1774528560,"startTime":"0","endTime":"0","summary":"红星资本局3月26日消息，一款在2022年就被传出缺货的进口乙肝疫苗，宣布重返中国市场。3月25日，葛兰素史克（GSK）宣布与科园信海（北京）医疗用品贸易有限公司（简称“上药科园贸易”）就乙肝疫苗安在时（EngerixB，重组乙型肝炎疫苗（酿酒酵母））启动战略合作。GSK表示，2026年正值安在时全球上市40周年，此次重返中国市场是满足市场需求的有力举措。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603263685856696.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4614","BK4532","CQQQ","BK4504","GSK","ASHR","GSKH","BK4588","LU0963586101.USD","ASHS","LU1829250122.USD","BK4007","BK4585","DRAG","GSK.UK","KWEB"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.gsk.com","stockEarnings":[{"period":"1week","weight":0.0194},{"period":"1month","weight":0.0196},{"period":"3month","weight":-0.0549},{"period":"6month","weight":0.0642},{"period":"1year","weight":0.252},{"period":"ytd","weight":0.0506}],"compareEarnings":[{"period":"1week","weight":-0.025},{"period":"1month","weight":0.0051},{"period":"3month","weight":0.0969},{"period":"6month","weight":0.0756},{"period":"1year","weight":0.2437},{"period":"ytd","weight":0.0816}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"GSK Plc于1999年12月6日在英国成立的公众服务有限公司，是一个世界领先的研究型制药和保健公司，由Glaxo Wellcome plc和SmithKline Beecham plc合并而成。公司致力于开发较现有治疗方案明显改善的新产品，为病人和政府、保险公司或其他第三方提供帮助。","yearOnYearQuotes":[{"month":1,"riseRate":0.586957,"avgChangeRate":0.013809},{"month":2,"riseRate":0.478261,"avgChangeRate":0.001243},{"month":3,"riseRate":0.608696,"avgChangeRate":0.019112},{"month":4,"riseRate":0.659574,"avgChangeRate":0.030828},{"month":5,"riseRate":0.404255,"avgChangeRate":-0.008644},{"month":6,"riseRate":0.595745,"avgChangeRate":0.009855},{"month":7,"riseRate":0.543478,"avgChangeRate":0.003945},{"month":8,"riseRate":0.586957,"avgChangeRate":0.005806},{"month":9,"riseRate":0.521739,"avgChangeRate":0.005973},{"month":10,"riseRate":0.521739,"avgChangeRate":0.013062},{"month":11,"riseRate":0.478261,"avgChangeRate":0.009917},{"month":12,"riseRate":0.608696,"avgChangeRate":0.014188}],"exchange":"NYSE","name":"葛兰素史克","nameEN":"GlaxoSmithKline PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"葛兰素史克(GSK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供葛兰素史克(GSK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"葛兰素史克,GSK,葛兰素史克股票,葛兰素史克股票老虎,葛兰素史克股票老虎国际,葛兰素史克行情,葛兰素史克股票行情,葛兰素史克股价,葛兰素史克股市,葛兰素史克股票价格,葛兰素史克股票交易,葛兰素史克股票购买,葛兰素史克股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"葛兰素史克(GSK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供葛兰素史克(GSK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}